Clinical report reassesses therapeutic response to monoclonal antibody 3F8 in oncology patients, highlighting crucial considerations for antibody-guided cancer therapy.
Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1992.10.4.671 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 1548529 Reassessment of patient response to monoclonal antibody 3F8. N V CheungxN V CheungSearch for articles by this author , H LazarusxH LazarusSearch for articles by this author , F D MiraldixF D MiraldiSearch for articles by this author , N A BergerxN A BergerSearch for articles by this author , C R AbramowskyxC R AbramowskySearch for articles by this author , U M SaarinenxU M SaarinenSearch for articles by this author , T SpitzerxT SpitzerSearch for articles by this author , S E StrandjordxS E StrandjordSearch for articles by this author , P F CocciaxP F CocciaSearch for articles by this author Show More https://doi.org/10.1200/JCO.1992.10.4.671 PDF "Reassessment of patient response to monoclonal antibody 3F8.." Journal of Clinical Oncology, 10(4), pp. 671–672© 1992 by American Society of Clinical Oncology
No takes yet. Share an insight, caveat, or question.
Cheung et al. (1992) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: